Xolair Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of asthma and allergic disorders, expansion of biologic drug approvals, rising diagnosis rates of chronic urticaria, availability of specialty allergy clinics, growing physician familiarity with monoclonal antibodies.

The growth in the forecast period can be attributed to increasing demand for personalized allergy treatments, expansion of biologics into additional inflammatory indications, rising investments in immunology research, growing adoption of long-acting injectable therapies, improved access to specialty biologic drugs. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising demand for biologic treatments in chronic allergic conditions, expansion of long-term disease management approaches, growing focus on precision immunology treatments, enhanced emphasis on patient-centric biologic care.

The rising prevalence of asthma is expected to drive growth in the Xolair market. Asthma is a chronic respiratory condition characterized by airway inflammation and narrowing, leading to wheezing, coughing, and difficulty breathing. Its increasing prevalence is linked to factors such as higher exposure to environmental pollutants, rising temperatures, changing weather patterns, and growing population density. Xolair (omalizumab) treats asthma by targeting IgE antibodies, reducing airway inflammation, and preventing attacks in patients with moderate to severe allergic asthma. For instance, in December 2024, data from the U.S.-based National Center for Health Statistics (NCHS) reported that the prevalence of current asthma among adults aged 18 and over rose from 3.7% in 2022 to 3.8% in 2023. Therefore, the growing prevalence of asthma is driving the Xolair market.

A key trend in the Xolair market is the expansion of approved indications, particularly in allergy and immunology, to broaden patient access and address unmet needs. IgE-mediated food allergies involve immune responses triggered by immunoglobulin E (IgE) antibodies, leading to rapid allergic reactions upon exposure to specific allergens. In February 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, received FDA approval for Xolair to reduce allergic reactions, including anaphylaxis, in patients aged 1 and older with IgE-mediated food allergies. This made Xolair the first FDA-approved treatment to reduce allergic reactions to multiple food allergens, though it is not intended for emergency use, and patients must continue avoiding allergens.

In October 2023, Alvotech, a Luxembourg-based biotechnology company, entered into a licensing agreement with Kashiv Biosciences to develop AVT23, a biosimilar to Xolair. The collaboration focuses on developing AVT23 for the treatment of allergic asthma and chronic spontaneous urticaria. Kashiv Biosciences, a U.S.-based biopharmaceutical company, specializes in the development and manufacturing of Xolair biosimilars, expanding treatment accessibility and affordability.

Major companies operating in the xolair market are F. Hoffmann-La Roche AG, Novartis AG.

North America was the largest region in the xolair market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xolair market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xolair market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the xolair market by raising costs for imported biologic manufacturing inputs, cell culture media, specialized filtration systems, and cold-chain distribution components. Hospital pharmacies and specialty clinics in North America and Europe are most affected due to reliance on international biologics supply chains, while Asia-Pacific faces cost pressure related to biologic imports and logistics. These tariffs are increasing treatment costs and affecting reimbursement dynamics. At the same time, they are encouraging regional biologics manufacturing expansion, local fill-and-finish operations, and long-term investments in domestic immunology drug production.

The xolair market research report is one of a series of new reports that provides xolair market statistics, including xolair industry global market size, regional shares, competitors with a xolair market share, detailed xolair market segments, market trends and opportunities, and any further data you may need to thrive in the xolair industry. This xolair market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Xolair (omalizumab) is a monoclonal antibody used to treat moderate to severe asthma, chronic idiopathic urticaria (hives), and nasal polyps. It works by targeting and inhibiting immunoglobulin E (IgE), an antibody involved in allergic reactions, thereby reducing inflammation and improving symptom control. Xolair is typically prescribed for patients whose conditions are not adequately managed with standard therapies.

The main indications for Xolair include asthma, chronic spontaneous urticaria (CSU), and nasal polyposis. In asthma, omalizumab is used to manage moderate to severe allergic asthma by reducing airway inflammation and preventing attacks in patients unresponsive to standard treatments. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult, geriatric, and pediatric patients.

The xolair market consists of sales of subcutaneous injections with 150 mg/1.2 mL prefilled syringes and 75 mg/0.5 mL prefilled syringes. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.